BerGenBio ASA (BGBIO.OL)

NOK 1.67

(-2.0%)

Total Liabilities Summary of BerGenBio ASA

BerGenBio ASA's latest annual total liabilities in 2023 was 46.85 Million NOK , down -40.08% from previous year.
BerGenBio ASA's latest quarterly total liabilities in 2024 Q2 was 43.2 Million NOK , up 2.6% from previous quarter.
BerGenBio ASA reported annual total liabilities of 78.2 Million NOK in 2022, up 18.84% from previous year.
BerGenBio ASA reported annual total liabilities of 65.8 Million NOK in 2021, down -3.18% from previous year.
BerGenBio ASA reported quarterly total liabilities of 43.2 Million NOK for 2024 Q2, up 2.6% from previous quarter.
BerGenBio ASA reported quarterly total liabilities of 46.85 Million NOK for 2023 FY, down -40.08% from previous quarter.

Annual Total Liabilities Chart of BerGenBio ASA (2023 - 2014)

Historical Annual Total Liabilities of BerGenBio ASA (2023 - 2014)

Year	Total Liabilities	Total Liabilities Growth
2023	46.85 Million NOK	-40.08%
2022	78.2 Million NOK	18.84%
2021	65.8 Million NOK	-3.18%
2020	67.97 Million NOK	34.27%
2019	50.62 Million NOK	21.85%
2018	41.54 Million NOK	22.24%
2017	33.98 Million NOK	59.81%
2016	21.26 Million NOK	20.52%
2015	17.64 Million NOK	421.46%
2014	-5.48 Million NOK	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	42.11 Million NOK	-10.13%
2024 Q2	43.2 Million NOK	2.6%
2023 FY	46.85 Million NOK	-40.08%
2023 Q3	26.83 Million NOK	-48.8%
2023 Q1	67.28 Million NOK	-13.97%
2023 Q4	46.85 Million NOK	74.62%
2023 Q2	52.4 Million NOK	-22.11%
2022 Q4	78.2 Million NOK	10.75%
2022 FY	78.2 Million NOK	18.84%
2022 Q1	72.56 Million NOK	10.26%
2022 Q2	82.03 Million NOK	13.05%
2022 Q3	70.61 Million NOK	-13.91%
2021 FY	65.8 Million NOK	-3.18%
2021 Q4	65.8 Million NOK	1.44%
2021 Q3	64.87 Million NOK	-7.17%
2021 Q2	69.88 Million NOK	-5.48%
2021 Q1	73.93 Million NOK	8.78%
2020 Q2	56.47 Million NOK	3.43%
2020 Q1	54.6 Million NOK	7.86%
2020 FY	67.97 Million NOK	34.27%
2020 Q4	67.97 Million NOK	28.57%
2020 Q3	52.86 Million NOK	-6.39%
2019 Q2	33.71 Million NOK	-17.65%
2019 Q1	40.94 Million NOK	-1.45%
2019 FY	50.62 Million NOK	21.85%
2019 Q3	33.74 Million NOK	0.07%
2019 Q4	50.62 Million NOK	50.03%
2018 Q3	32.76 Million NOK	4.88%
2018 Q1	44.76 Million NOK	31.71%
2018 FY	41.54 Million NOK	22.24%
2018 Q4	41.54 Million NOK	26.81%
2018 Q2	31.23 Million NOK	-30.22%
2017 Q4	33.98 Million NOK	56.2%
2017 Q3	21.75 Million NOK	-19.64%
2017 Q2	27.07 Million NOK	0.0%
2017 FY	33.98 Million NOK	59.81%
2016 Q4	21.26 Million NOK	0.0%
2016 FY	21.26 Million NOK	20.52%
2015 FY	17.64 Million NOK	421.46%
2014 FY	-5.48 Million NOK	0.0%

Peer Total Liabilities Comparison of BerGenBio ASA

Name	Total Liabilities	Total Liabilities Difference
Arctic Bioscience AS	41.69 Million NOK	-12.387%
Aqua Bio Technology ASA	15.72 Million NOK	-198.027%
ArcticZymes Technologies ASA	30.02 Million NOK	-56.061%
Hofseth BioCare ASA	348.97 Million NOK	86.573%
PCI Biotech Holding ASA	5 Million NOK	-835.683%
Thor Medical ASA	58.91 Million NOK	20.457%
Ultimovacs ASA	69.64 Million NOK	32.72%